Seeking Alpha

Not all diagnostics companies are worried at the prospect of the Supreme Court striking down...

Not all diagnostics companies are worried at the prospect of the Supreme Court striking down patents on two cancer-related genes "owned" by Myriad (MYGN) in a decision that is due to come in 2013. Quest (DGX) says it could be a "positive development," as it would "open new opportunities to develop new testing services." Myriad, which has spent 17 years and $500M on isolating the "DNA molecules and processes," isn't so sanguine.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector